argenex SE $ARGX Shares Sold by First Trust Advisors LP

First Trust Advisors LP cut its holdings in shares of argenex SE (NASDAQ:ARGX) by 4.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 58,770 shares of the company’s stock after selling 2,630 shares during the period. First Trust Advisors LP owned about 0.10% of argenex worth $32,395,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ARGX. Franklin Resources Inc. increased its holdings in argenex by 103.9% during the 2nd quarter. Franklin Resources Inc. now owns 279,803 shares of the company’s stock worth $154,233,000 after purchasing an additional 142,606 shares during the last quarter. Lord Abbett & CO. LLC increased its stake in shares of argenex by 33.2% in the first quarter. Lord Abbett & CO. LLC now owns 274,700 shares of the company’s stock worth $162,585,000 after buying an additional 68,498 shares during the last quarter. Millennium Management LLC boosted its stake in argenex by 316.9% during the 1st quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock valued at $158,977,000 after acquiring an additional 204,180 shares during the last quarter. Jennison Associates LLC boosted its stake in argenex by 6.1% during the 2nd quarter. Jennison Associates LLC now owns 264,647 shares of the company’s stock valued at $145,879,000 after acquiring an additional 15,186 shares during the last quarter. Finally, American Century Companies Inc. grew its holdings in argenex by 38.3% during the 2nd quarter. American Century Companies Inc. now owns 205,906 shares of the company’s stock worth $113,503,000 after acquiring an additional 57,054 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ARGX. Guggenheim restated a “buy” rating and issued a $1,070.00 target price on shares of argenex in a research note on Thursday, September 18th. Truist Financial upped their price objective on argenex from $700.00 to $918.00 and gave the company a “buy” rating in a research note on Monday, September 15th. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research report on Wednesday, October 8th. Royal Bank Of Canada raised their price objective on argenex from $850.00 to $860.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Finally, Zacks Research lowered shares of argenex from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $917.39.

argenex Price Performance

NASDAQ:ARGX opened at $890.11 on Thursday. argenex SE has a 12-month low of $510.05 and a 12-month high of $934.62. The business has a 50 day simple moving average of $859.76 and a 200 day simple moving average of $713.03. The firm has a market capitalization of $54.80 billion, a P/E ratio of 38.22, a P/E/G ratio of 0.89 and a beta of 0.37.

argenex (NASDAQ:ARGX) last posted its earnings results on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.37 by $0.03. The company had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.07 billion. argenex had a return on equity of 29.78% and a net margin of 41.58%. Research analysts anticipate that argenex SE will post 3.13 EPS for the current fiscal year.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.